#3067
Somatostatin Analogs in Real‐World Practice for Patients with Metastatic Neuroendocrine Tumors: A Single Institution Experience in the Ouest of Algeria (CHU Oran)
Introduction:
The efficacy of somatostatin analogs (SSAs) were clearly established trough pivotal trials as first‐line agents for neuroendocrine tumors (NETs), but their use in clinical practice is largely unknown.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Authors:
Ameziane N,
Behourah Z,
Aida M,
Ahed Messaoud M,
Bousahba A,
Keywords:
GEP-NET,
Somatostatin analogs,
anti proliferative action,
anti secretory action,
Management real world practice,
#3047
Functional Consequence of β-Arrestin 1 Gene Knock-Out in Pancreatic Neuroendocrine Tumor Cell Line BON-1
Introduction:
An important limiting factor influencing treatment efficacy of neuroendocrine tumors (NETs) with somatostatin analogs (SSA) is the availability of somatostatin receptors (SSTR) on NETs. While downregulation or altered pattern of SSTR expression are important considerations, receptor internalization/desensitization by β-arrestins may be a crucial contributing factor. Interestingly, our previous study showed a preferential higher expression of β-arrestin 1 (ARRB1), in gastroenteropancreatic NETS (GEP-NETs) compared to pituitary adenomas.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Iyer A
Authors:
Iyer A,
Vriens J,
Dogan-Oruç F,
van Koetsveld P,
Hofland L,
Keywords:
β-arrestin 1,
CRISPR-Cas9,
BON-1,
knock-out,
SSTR,
SSA,
Pan-NET,
#3040
Palliative CT Brachytherapy in Hepatic Metastatic NET
Introduction:
Hepatic metastases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may induce prognosis relevant complications in an otherwise stable systemic disease after resection of the primary.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Jann H
Authors:
Feldhaus F,
Jann H,
Jonczyk M,
Boening G,
Wieners G,
Keywords:
brachytherapy,
afterloading,
hepatic metastases,
local tumor ablation,
local tumor control,
#3034
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Is There Any Benefit When Ki-67 Is ≥ 10%?
Introduction:
The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Merola E
Authors:
Merola E,
Alonso Gordoa T,
Zhang P,
Al-Toubah T,
Pelle E,
Keywords:
Pancreatic NET,
Somatostatin Analogs,
Grade 2 and 3,
Safety,
Efficacy,
